Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that vesicles formed with behenyltrimethylammonium chloride, stearic acid, and hinokitiol significantly improved skin permeation of hinokitiol in vitro, which may aid in hair growth promotion.

This study found that both ethanol and aqueous extracts of Lepidium sativum seeds improved insulin signaling and reduced obesity-related metabolic changes in high-fat diet-fed rats, suggesting potential as a dietary supplement.

This study found that stem cells can temporarily act as non-professional phagocytes during hair cycle regeneration by clearing apoptotic cells through a process requiring local lipids and retinoids for activation, providing insights into their dual role in maintaining tissue integrity.

This research found significant associations between gut microbiome composition and 14 out of 37 examined health conditions, suggesting that increased microbial abundance often aligns with favorable health states.

This study found that the viscosity of silicone oil in hair treatments significantly affects wave curling performance and hair damage, with untreated and chemically treated hair showing different optimal viscosities.

This review examines current knowledge on human epithelial hair follicle stem cells, their markers, and outlines challenges in translating findings from murine studies to human research, but does not report new experimental results.

This review highlights how advanced nanocarrier and microneedle-based transdermal drug delivery strategies can potentially improve the treatment of skin diseases by enhancing site-specific drug delivery, increasing skin penetration, and reducing systemic toxicity compared to conventional methods.

This study found that dermatologists in an urban academic setting most frequently use topical corticosteroids, intralesional corticosteroids, and topical minoxidil for treating central centrifugal cicatricial alopecia, aligning with current literature recommendations on reducing inflammation.

This study found that a regimen combining cyproterone acetate and testosterone buciclate induced reversible azoospermia in bonnet monkeys, highlighting its potential as an effective male contraceptive.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

In this study, BTXA injections did not effectively treat recalcitrant alopecia areata or improve hair regrowth in most patients, suggesting its limitations as an alternative therapy.

This study found that intramuscular triamcinolone acetonide may be an effective and safe treatment option for managing refractory alopecia areata, showing a 63% response rate in patients and hair regrowth negatively correlated with initial scalp involvement.

This study found that administering botulinum toxin A via Flex-PADs to mouse footpads inhibited sweating similarly to traditional injections, suggesting a promising patient-friendly delivery method for hyperhidrosis treatment.

In this case report, the authors observed that onabotulinum toxin A therapy, extended to areas around traumatic excoriations and alopecia, resulted in notable healing and hair regrowth in a patient with trigeminal trophic syndrome and trichotillomania.

This study suggests that oral tofacitinib may be an effective treatment for beard regrowth in men with alopecia areata of the beard, with a strong correlation observed between beard and scalp hair regrowth.

This review discusses the various therapeutic uses of Botulinum Toxin Type A and reports high levels of patient satisfaction with minimal adverse effects across several conditions, emphasizing its potential therapeutic importance.

This study found that both 2.5 mg/mL and 5 mg/mL concentrations of intralesional triamcinolone acetonide are effective for treating patchy alopecia areata, but the higher concentration promoted greater hair regrowth and density with more side effects.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This case report describes a woman with trichotillomania who experienced marked improvement and hair regrowth after off-label onabotulinumtoxinA treatment.

In this study, retrospective analysis of patients with severe alopecia areata showed that oral JAK inhibitors, tofacitinib and baricitinib, reduced hair loss significantly, with comparable effectiveness; longer tofacitinib use was linked to greater improvement, while baricitinib achieved substantial outcomes quickly.

In this study, triamcinolone acetonide injections led to partial hair regrowth in 60% of alopecia totalis patients, suggesting potential benefits when followed by immunotherapy.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

In this study, oral tofacitinib showed higher efficacy and tolerability in treating refractory alopecia totalis and universalis compared to traditional treatments, achieving a 50% improvement in severity scores for 44.4% of patients over six months, with fewer adverse effects.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

This study found that tofacitinib and baricitinib had an acceptable adverse reaction profile when used to treat rheumatoid arthritis, with similar side effects to those described in their technical data sheets.